Jack Phillips - 13 Feb 2023 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Feb 2023, 17:30:07 UTC
Prior SEC filing
01 Feb 2023
Next SEC filing
13 Mar 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Steven Reichling, attorney-in-fact

Key filing fact

Jack Phillips filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 15 Feb 2023.

Key facts

  • This page summarizes Jack Phillips's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 15 Feb 2023, 17:30.

Change

  • Previous filing in this sequence was filed on 01 Feb 2023.
  • Current net transaction value: -$5,161.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXDX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+17,216
Change %
+6.6%
Price
$0.000000
Shares after
278,059
Date
13 Feb 2023
Ownership
Direct
Footnotes
F1
AXDX transaction

Common Stock

Sale

Transaction value
$5,161
Shares
-8,601
Change %
-3.1%
Price
$0.6000
Shares after
269,458
Date
13 Feb 2023
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXDX transaction Derivative

Employee Restricted Stock Units

Award

Transaction value
$0
Shares
+350,000
Change %
Price
$0.000000
Shares after
350,000
Date
13 Feb 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
350,000
Exercise price
Footnotes
F3, F4, F5
AXDX transaction Derivative

Employee Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-17,216
Change %
-100%
Price
$0.000000*
Shares after
0
Date
13 Feb 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,216
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On May 20, 2021, the reporting person was granted a total of 206,597 restricted stock units, which vests in equal amounts every month for 12 months.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F4

The reporting person received restricted stock units on February 13, 2023, which will vest on March 8, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

Footnote F5

Not Applicable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .